Welcome to our dedicated page for AMICUS THERAPEUTICS SEC filings (Ticker: FOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AMICUS THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AMICUS THERAPEUTICS's regulatory disclosures and financial reporting.
Amicus Therapeutics, Inc. common stock is the subject of this amended beneficial ownership report by The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC. The reporting persons state that they beneficially own 0 Amicus shares, representing 0.0% of the class, with no sole or shared voting or dispositive power over any shares as of the reported date.
The filing confirms that the reporting persons now hold ownership of 5 percent or less of Amicus’s common stock. Goldman Sachs & Co. LLC, a registered broker-dealer and investment adviser and a subsidiary of The Goldman Sachs Group, Inc., is identified as the operating entity through which securities are, or may be deemed to be, beneficially owned. A Joint Filing Agreement authorizes joint and amended filings, and the Goldman Sachs reporting units disclaim beneficial ownership of securities held in certain client accounts and investment entities.
Barclays PLC reported beneficial ownership of 17,755,672 shares of Amicus Therapeutics Inc common stock, representing 5.65% of the class. The filing shows sole voting power of 17,747,658 shares and shared voting power of 8,014. The report is signed on 05/14/2026.
Amicus Therapeutics ownership disclosure: The filing reports that The Goldman Sachs Group, Inc. and affiliate Goldman Sachs & Co. LLC together hold 16,782,162.81 shares of Amicus common stock, representing 5.3% of the class, with shared voting and shared dispositive power reported.
The filing is a joint Schedule 13G statement executed by GS Group and Goldman Sachs & Co. LLC and includes exhibits identifying the reporting subsidiary relationship and a joint filing agreement.
Amicus Therapeutics reports that UBS Group and its subsidiaries beneficially own 17,141,817 shares of Common Stock, representing 5.46% of the class. The filing states UBS Group AG filed on behalf of UBS Financial Services Inc., UBS Securities LLC, UBS AG London Branch and UBS Switzerland AG. The filer reports shared voting power of 17,071,007 shares and shared dispositive power of 14,222,423.
Amicus Therapeutics, Inc. received a Schedule 13G filing from Glazer Capital, LLC and Paul J. Glazer identifying themselves as former large holders. The filing states the Reporting Persons currently beneficially own 0 shares of Amicus common stock (CUSIP 03152W109) representing 0% of the class.
The statement notes the Reporting Persons "have ceased to be the beneficial owner of more than five percent of the class of securities." The filing lists the Reporting Persons' business address and is signed by Paul J. Glazer on 05/01/2026.